HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

NCT07575308 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Von Willebrand Disease (VWD)
Heavy Menstrual Bleeding (HMB)

Interventions

DRUG: ALN-6400

Sponsor

Alnylam Pharmaceuticals